Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Myostatin HMP (GDF8)Explore study findings

What lean mass preservation meant in the EMBRAZE trial

2 numbered sourcesSource years 2026

Amino acids form short chains called peptides when they are connected by peptide bonds. Some take part in the signaling that shapes body composition. GDF8, or myostatin, is a larger protein signal that restrains muscle growth. The catalog shorthand “HMP” leaves its exact form unclear. A 2026 human study called EMBRAZE examined a precisely identified antibody against myostatin activation and asked whether it changed the amount of lean tissue lost during weight reduction with tirzepatide. [1]

In this phase 2 trial, adults with overweight or obesity received tirzepatide and were randomly assigned to apitegromab or placebo. All participants therefore had the same background treatment. The blinded comparison was designed to estimate the effect of adding the antibody. Apitegromab binds precursor forms of myostatin, leaving less of the protein available to act as a growth-limiting signal. The researchers also tracked a blood marker of its interaction with latent myostatin. [1]

Total weight loss was similar between the groups, while the antibody group lost less lean mass on average. A body composition scan separates body weight into compartments. The lean compartment includes skeletal muscle and other nonfat soft tissue. Its estimate can also be affected by body water. Preserving more of that compartment is a different finding from demonstrating larger muscles, greater strength or easier everyday movement. The main study outcome answered a body composition question, and the paper discussed the need for further work on clinical function. [1]

The authors reported broadly similar proportions of participants with adverse events across the study groups. A trial of this size and duration gives an early view of what was observed in the enrolled group. Less common events and longer-term clinical outcomes would require evidence from a larger or longer study. Researchers would also need to establish how well the pattern applies to people whose health or baseline muscle function differs from that of the trial participants. [1]

The later U.S. approval of apitegromab-mstn concerns spinal muscular atrophy in people already receiving an SMN2-targeted treatment. EMBRAZE addressed an investigational use in a different population with a different outcome and a different companion medicine. It is best read as evidence about the studied comparison and its scan-based endpoint. The research question is whether the observed difference in lean tissue leads to functional benefits that matter to patients. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop Myostatin HMP (GDF8)

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.